6:12 PM
 | 
Mar 04, 2013
 |  BC Extra  |  Company News

FDA to review Biogen Idec's hemophilia B therapy

Biogen Idec Inc. (NASDAQ:BIIB) said FDA accepted for review a BLA for rFIXFc to treat hemophilia B. Biogen Idec...

Read the full 85 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >